Revenue from operations rose 43% YoY to Rs 381.43 crore during the period under review. Profit before tax in Q1 FY22 stood at Rs 61.29 crore, up 155.06% as against Rs 24.03 crore in Q1 FY21. Current tax outgo surged 137.47% YoY to Rs 27.38 crore during the period under review.

On a standalone basis, during the first quarter of FY 2021-22, revenues of Indoco Remedies grew by 42.9% at Rs 381.2 crores, as against Rs 266.8 crore, same quarter last year. EBIDTA to net sales for the quarter is 22.8% at Rs 86.8 crore, compared to 18.3% at Rs 48.9 crore, same quarter last year. For the quarter, the profit after tax to net sales is 10.4% at Rs 39.6 crore, compared to 6.5% at Rs 17.20 crore, same quarter last year.

Aditi Panandikar, managing director, Indoco Remedies, said, “Our India & International businesses have shown a robust growth this quarter. We have optimized the opportunities presented by this very dynamic business environment as well as effectively adapted to the challenges thus presented.”

Indoco Remedies is a fully integrated, research-oriented pharma Company with presence in 55 countries.